wells fargo dsip portfolio Steve Cambouris - Wells Fargo raises year-end S&P

We've supplied high-purity BPC-157 for gastrointestinal research protocols where iNOS modulation is the primary endpoint

BPC-157 emerges as a promising therapeutic peptide for improving bone and joint good health

This was conducted with brain (or vein) images for healthy rats, and then for both the control (saline) group and the treated (BPC 157) group of rats at the same intervals after the application and at the time of sacrifice

BPC 157 was given per-orally, in drinking water (10 g/kg, 10 ng/kg, i.e., 0.16 g/ml, 0.16 ng/ml, and 12 ml/rat/day) till sacrifice, or alternatively, 10 g/kg and 10 ng/kg intraperitoneally